| Small cell carcinoma of lung
Zepzelca vs Tecentriq
Side-by-side clinical, coverage, and cost comparison for small cell carcinoma of lung.Deep comparison between: Zepzelca vs Tecentriq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecentriq has a higher rate of injection site reactions vs Zepzelca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecentriq but not Zepzelca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zepzelca
Tecentriq
At A Glance
IV infusion
Every 21 days
Alkylating drug
IV infusion
Every 2-4 weeks
PD-L1 antagonist
Indications
- Small cell carcinoma of lung
- Small cell lung cancer extensive stage
- Small cell lung cancer metastatic
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
Dosing
Small cell lung cancer extensive stage 3.2 mg/m2 IV infusion over 60 minutes every 21 days in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs until disease progression or unacceptable toxicity; reduce to 1.6 mg/m2 every 21 days for moderate or severe hepatic impairment.
Small cell lung cancer metastatic 3.2 mg/m2 IV infusion over 60 minutes every 21 days as a single agent until disease progression or unacceptable toxicity; reduce to 1.6 mg/m2 every 21 days for moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Contraindications
—
—
Adverse Reactions
Most common (>=30%) Decreased lymphocytes, decreased platelets, decreased hemoglobin, decreased neutrophils, nausea, fatigue
Serious Pneumonia, sepsis, cardio-respiratory arrest, myocardial infarction, febrile neutropenia
Postmarketing Extravasation with tissue necrosis requiring debridement, rhabdomyolysis, tumor lysis syndrome
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Pharmacology
Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts that disrupt DNA binding proteins and repair pathways, leading to cell cycle perturbation and cell death; it also inhibits monocyte activity and reduces macrophage tumor infiltration in vivo.
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zepzelca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Zepzelca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zepzelca
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10
JazzCares Copay Program: ZepzelcaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tecentriq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZepzelcaView full Zepzelca profile
TecentriqView full Tecentriq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.